Original site: www.cdc.gov/mmWR/preview/mmwrhtml/00042591.htm | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.

[More]
About Us Report Bug

RestoredCDC.org Comparison

Comparison timestamp: 2025-05-02 17:33:22 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/mmWR/preview/mmwrhtml/00042591.htm
Live cdc.gov URL ↗: https://www.cdc.gov/mmWR/preview/mmwrhtml/00042591.htm
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected: Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/mmWR/preview/mmwrhtml/00042591.htm | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
[More]
About Us Report Bug Compare Content
Weekly
June 14, 1996 / 45(23);494-495
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers Availability of Parenteral Quinidine Gluconate for Treatment of Severe or Complicated Malaria
CDC has received reports of two fatal cases of Plasmodium falciparum malaria in the United States in which a delay in obtaining quinidine gluconate for intravenous therapy was thought to have played a role in the patients' deaths. Since 1991, quinidine gluconate, a well-known and widely used class Ia anti-arrhythmic agent, has been the only parenteral antimalarial drug available in the United States. It is the drug of choice for treating serious and life-threatening malaria infections and is active against drug-resistant strains of P. falciparum. Intravenous quinidine is indicated whenever oral therapy is not possible, in high-density infections (greater than 5% of red blood cells infected), and in the presence of complications such as cerebral malaria or acute renal failure.
As newer anti-arrhythmic agents have replaced quinidine for many of its cardiac indications, some hospitals and health facilities have dropped quinidine gluconate from their formularies. Although most patients with malaria reported in the United States are treated with oral medication and recover fully, a small number of fatal cases occur each year, often associated with substantial delays in seeking treatment or in initiating appropriate antimalarial therapy. Because of this potential problem, directors of hospital drug services should take into account the essential role of quinidine gluconate in treating patients with severe and complicated malaria before removing it from their formularies. Hospitals within close geographic proximity are encouraged to coordinate their respective formularies so that quinidine gluconate
Reported by: Food and Drug Administration. Div of Parasitic Diseases, National Center for Infectious Diseases, CDC.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
Page converted: 09/19/98
HOME | ABOUT MMWR | MMWR SEARCH | DOWNLOADS | RSS | CONTACT
POLICY | DISCLAIMER | ACCESSIBILITY
Department of Health
Morbidity and Mortality Weekly Report and Human Services
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A
This page last reviewed 5/2/01
Note: Comparison ignores leading/trailing whitespace and certain script/tracking codes. Word-level highlighting (optional above) only applies to changed lines.